Shire Share Discussion Threads

[steeplejack] 11/7/2017 10:18

Large cap pharmas are off some 10% in the last month.

[a2584728] 11/7/2017 10:14

Where is the bottom of down trend .????

[philanderer] 11/7/2017 09:19

11th july JP Morgan Caz overweight tp 6000p

reiterates

[philanderer] 10/7/2017 14:53

Downtrend now firmly in place.

[philanderer] 10/7/2017 09:10

10th july Liberum hold tp 4900p

reiterates

[philanderer] 07/7/2017 09:29

7th july RBC outperform


reiterates

[philanderer] 06/7/2017 12:16

Shire: HSBC upgrades to Hold with a target price of 4450p.

...... it said the drugmaker's haemophilia headline risk from rival Roche's plans was now "largely in the price".

[bigboots] 05/7/2017 14:52

Talk of a bid from a US rival.....

[wobaguk] 04/7/2017 13:13

The trend is downward but I would be surprised if we didnt see almost 4500 again soon before another drop. If so I may exit then.

[philanderer] 03/7/2017 20:56

Sales For Shire's PLC (ADR) (NASDAQ:SHPG) HAE Franchise To Reach $1.9B By 2021

[philanderer] 30/6/2017 09:40

Looks like 4000p next chart support.

updated from the experts ;-)

30th june Deutsche buy tp 6000p
28th june Goldman Sachs conviction buy tp 6800p
28th june Liberum hold tp 4900p
27th june JP Morgan overweight -
27th june RBC outperform -
27th june Credit Suisse outperform tp 5350p
22nd june Citigroup buy tp 6500p
22nd june ShoreCap buy -
21st june Cantor buy tp 6300p
9th june Barclays overweight tp 6300p
9th june Jefferies buy tp 5600p
8th june Berenberg buy tp 6000p
26th may Bernstein market perform -
23rd may Soc Gen buy tp 7500p
3rd may HSBC reduce tp 4450p


3rd may ++++ Results ++++

[steeplejack] 29/6/2017 15:40

Someone must make good money trading this stock...it's not me.

[philanderer] 29/6/2017 14:15

£ at one month high.

[philanderer] 28/6/2017 13:12

Goldmans cuts tp to 6400p from 6800p - retains 'conviction buy'


28th june Liberum hold tp 4900p reiteration

[philanderer] 27/6/2017 08:53

27th june JP Morgan overweight =
27th june RBC outperform =
27th june Deutsche buy tp 6000p
27th june Credit Suisse outperform tp 5350p

[philanderer] 26/6/2017 17:08

EU regulators reviewing Shire’s bleeding disorder drug

[philanderer] 24/6/2017 10:13

Biocryst and Shire under pressure on FDA approval of Behring's HAE med

[philanderer] 23/6/2017 17:42

Zug, Switzerland - June 23, 2017

- Shire plc (LSE: SHP, NASDAQ: SHPG), a leading biotechnology company focused on serving individuals with rare diseases, will present research covering a broad range of rare bleeding disorders at the 26th Biennial International Society on Thrombosis and Haemostasis Congress (ISTH), July 8-13, 2017 in Berlin, Germany.

Showcased in eight oral presentations, 29 poster presentations and three symposia, these data underscore Shire's pursuit of treatment innovation rooted in safety, efficacy, and individualized care for hemophilia patients.

[philanderer] 22/6/2017 10:04

Shire was the top riser in the FTSE 100, up 1.9% after the European Medicines Agency validated its marketing authorisation application for Veyvondi, which treats an inherited bleeding disorder called von Willebrand disease.

[philanderer] 22/6/2017 08:22

22nd june Citigroup buy tp 6500p

reiterates

[philanderer] 21/6/2017 08:43

Lexington, Mass., USA – June 20, 2017

– Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved MYDAYISTM (mixed salts of a single-entity amphetamine product), a once-daily treatment comprised of three different types of drug-releasing beads for patients 13 years and older with Attention Deficit Hyperactivity Disorder (ADHD).

Mydayis is not for use in children 12 years and younger. Shire expects to make Mydayis commercially available in the United States in the third quarter of 2017.

[philanderer] 21/6/2017 08:32

21st june Cantor buy tp 6300p
21st june ShoreCap hold -
21st june Liberum hold tp 4900p

reiterations

[philanderer] 13/6/2017 23:52

'Shire Investors Have Overreacted To Lialda News'